Metraipolis › archive › dc_bd09fc0e5242

P300/CBP inhibition with inobrodib in combination with gilteritinib and venetoclax targets leukemia stem cells in epigenetic mutant AML — Europe PMC PMID:42139346

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42139346
DOI
10.1126/sciadv.aec9305
License (as archived)
solo-consultazione
Archived
2026-11-02T07:22:43.525Z
SHA-256 of the archived text
fffa44301097e39a6b47804d2c8fcddfcbc8780f3782028a26d320aa3799df05
Stable URL of this page
https://metraipolis.com/documento/dc_bd09fc0e5242

How to cite

P300/CBP inhibition with inobrodib in combination with gilteritinib and venetoclax targets leukemia stem cells in epigenetic mutant AML — Europe PMC PMID:42139346 — Europe PMC (en), https://europepmc.org/article/MED/42139346 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_bd09fc0e5242 (Metraipolis archive dc_bd09fc0e5242, sha256 fffa44301097e39a6b47804d2c8fcddfcbc8780f3782028a26d320aa3799df05)
BibTeX
@misc{dcbd09fc0e5242,
  title = {P300/CBP inhibition with inobrodib in combination with gilteritinib and venetoclax targets leukemia stem cells in epigenetic mutant AML — Europe PMC PMID:42139346},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42139346},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_bd09fc0e5242; sha256 fffa44301097e39a6b47804d2c8fcddfcbc8780f3782028a26d320aa3799df05},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42139346. Agents can read the archived copy with the MCP tool read_document.